Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen

Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice

(2013) Ayako Takahashi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease

(2013) Jianhua He et al.   Clinical and Experimental Nephrology

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

(2013) P.-H. Groop et al.   DIABETES CARE

Origin and function of myofibroblasts in kidney fibrosis

(2013) Valerie S LeBleu et al.   NATURE MEDICINE

Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis

(2013) Keizo Kanasaki et al.   Frontiers in Endocrinology

DPP-4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes

(2012) Kim Alexander Connelly et al.   Cardiovascular Therapeutics

Pathophysiology of the aging kidney and therapeutic interventions

(2012) Keizo Kanasaki et al.   HYPERTENSION RESEARCH

Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis

(2012) Hal E Broxmeyer et al.   NATURE MEDICINE

Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity

(2012) Matthias Kern et al.   PLoS One

Therapy in the Early Stage: Incretins

(2011) S. Cernea et al.   DIABETES CARE

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function

(2011) Chinmay S. Marathe et al.   Experimental Diabetes Research

Effects of DPP-4 inhibition on cardiac metabolism and function in mice

(2011) M. Lenski et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy

(2011) Lyubov Chaykovska et al.   PLoS One

miR-29 Is a Major Regulator of Genes Associated with Pulmonary Fibrosis

(2010) Leah Cushing et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes

(2010) Nga N. Ta et al.   ATHEROSCLEROSIS

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

(2010) A. J. Scheen   DIABETES OBESITY & METABOLISM

The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

(2010) S. Blech et al.   DRUG METABOLISM AND DISPOSITION

High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells

(2010) Bin Du et al.   FEBS LETTERS

Renal Medullary MicroRNAs in Dahl Salt-Sensitive Rats

(2010) Yong Liu et al.   HYPERTENSION

Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV

(2010) Armanda Casrouge et al.   JOURNAL OF CLINICAL INVESTIGATION

The role of endothelial-to-mesenchymal transition in cancer progression

(2008) S Potenta et al.   BRITISH JOURNAL OF CANCER

Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation

(2008) W T Arscott et al.   ONCOGENE

Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis

(2008) E. van Rooij et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA